Real World Outcomes Of An Extended Depth-Of-Focus Iol Implanted In Spanish Clinics

To report Real World visual performance in patients bilaterally implanted with the AcrySof IQ Vivity and/or AcrySof IQ Vivity Toric Extended Depth of Focus IOL.

Multicenter, ambispective registry study conducted in Europe, Australia and New Zealand evaluating the performance of bilaterally implanted AcrySof Vivity and/or AcrySof Vivity Toric IOL in a real world setting through routine clinical practice.

This is a sub-analysis of subjects enrolled from Spanish sites. After a minimum of 3 months post-op follow up per local clinical practice standards, subjects implanted with the AcrySof IQ Vivity and/or AcrySof IQ Vivity Toric IOL in both eyes underwent visual performance assessments of visual acuity at distance, intermediate (66 cm) and near (40 cm) distances. Subject satisfaction and spectacle independence was recorded via validated questionnaires and patient reports of visual disturbances are reported.

910 subjects have been enrolled globally with 288 subjects (31.6%) among 10 Spanish sites. Mean UCDVA was 0.014 ± 0.096 logMAR (20/20 Snellen), mean UCIVA was 0.088 ± 0.125 logMAR (~ 20/25 Snellen) and mean UCNVA was 0.226 ± 0.151 logMAR (~20/32 Snellen). 94.5% reported to be satisfied and 74% report no difficulty in seeing the prices of goods when shopping. The % of subjects reporting never/rarely needing to wear eyeglasses to see up close was 60.8%, or at arm’s length 91% or far away 96.6% .Subjects reporting 'none' for halos was 89.6%, glare 92% and starbursts 91.3%.

Patients bilaterally implanted in Spanish clinics with the AcrySof IQ Vivity and AcrySof IQ Vivity Toric IOL evaluated in regular clinical settings suggests very good visual outcomes, high levels of vision patient satisfaction with low needs to wearing spectacles for intermediate and distance activities and also experiencing mild to none visual disturbances.